Orchard Therapeutics Stock (ORTX): $9 Price Target From Cantor Fitzgerald

By Amit Chowdhry ● Dec 29, 2021
  • The shares of Orchard Therapeutics PLC (NASDAQ: ORTX) have received a $9 price target from Cantor Fitzgerald. These are the details.

The shares of Orchard Therapeutics PLC (NASDAQ: ORTX) have received a $9 price target from Cantor Fitzgerald. And Cantor Fitzgerald analyst Pete Stavropoulos had assumed the coverage of Orchard Therapeutics with an “Overweight” rating while reducing the price target from $12.

Stavropoulos noted that Orchard is developing potentially curative gene therapies for rare diseases using autologous ex-vivo genetically modified hematopoietic stem cells (HSCs). And while Stavropoulos believes that the company’s HSC-based gene therapy platform is differentiated and clinically de-risked and sees the potential for increasing pipeline visibility to drive share price appreciation in 2022, he noted lingering concern about the regulatory filings for OTL-200 in metachromatic leukodystrophy in the U.S. and OTL-103 in Wiskott Aldrich syndrome in the U.S. and EU.

Plus Stavropoulos adjusted the estimates of the odds for success for these programs, which leads to the new price target.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.